Home |
Free Dividend Report |
Stock Splits Calendar |
OPXAW Historical Stock Prices |
Preferred Stock Newsletter |
Top Option Ideas |
Stock Message Boards |
OPXAW (OPXAW) has the following price history information. Looking back at OPXAW historical stock prices for the last five trading days, on February 11, 2013, OPXAW opened at $0.02, traded as high as $0.02 and as low as $0.01, and closed at $0.02. Trading volume was a total of 249.80K shares. On February 12, 2013, OPXAW opened at $0.02, traded as high as $0.02 and as low as $0.01, and closed at $0.01. Trading volume was a total of 995.10K shares. On February 13, 2013, OPXAW opened at $0.01, traded as high as $0.01 and as low as $0.01, and closed at $0.01. Trading volume was a total of 432.80K shares. On September 11, 2017, OPXAW opened at $0.08, traded as high as $0.08 and as low as $0.07, and closed at $0.08. Trading volume was a total of 719.10K shares. On September 12, 2017, OPXAW opened at $0.08, traded as high as $0.08 and as low as $0.07, and closed at $0.07. Trading volume was a total of 517.80K shares.
OPXAW Historical Stock Prices By Date:
Below, we examine the compound annual growth rate — CAGR for short — of an investment into OPXAW shares, starting with a $10,000 purchase of OPXAW, and working forward through the historical stock price information to today. No data found
OPXAW Historical Price Range | |||||
Date | Open | High | Low | Close | Volume |
02/11/2013 | $0.02 | $0.02 | $0.01 | $0.02 | 249.80K |
02/12/2013 | $0.02 | $0.02 | $0.01 | $0.01 | 995.10K |
02/13/2013 | $0.01 | $0.01 | $0.01 | $0.01 | 432.80K |
09/11/2017 | $0.08 | $0.08 | $0.07 | $0.08 | 719.10K |
09/12/2017 | $0.08 | $0.08 | $0.07 | $0.07 | 517.80K |
About OPXAW |
Opexa Therapeutics is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica. These therapies are based on Co.'s proprietary T-cell technology. Co.'s product candidates comprised of: Tcelna®, an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS, and is tailored to each patient's immune response profile to myelin; and OPX-212, an autologous T-cell immunotherapy for the treatment of neuromyelitis optica. Tcelna®, ImmPath® and Precision Immunotherapy® are registered trademarks of Co.'s. |
OPXAW Historical Closing Prices | |
Date | Close |
02/11/2013 | $0.02 |
02/12/2013 | $0.01 |
02/13/2013 | $0.01 |
09/11/2017 | $0.08 |
09/12/2017 | $0.07 |
Healthcare Historical Prices |
OPXAW is categorized under the Healthcare sector; below are some other companies in the same sector:
OREX Historical Stock Prices
Free OPXAW Email Alerts:
|
OPXAW Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2024, All Rights Reserved
Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.Want to receive our latest research absolutely free?
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.